TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
FLNA

Filana Therapeutics, Inc.

Healthcare · Biotechnology

0.72$ +5.2% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Filana Therapeutics, Inc. (FLNA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.9% of the shares are freely tradable; institutional investors hold 28.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 28.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 11.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 97.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 13.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 48Mio.

Largest Shareholders

Institutions

Institutions FLNA
Name Stake (%) Shares Change (%) Date
Marshall Wace Asset Management Ltd 4.17 2,012,543 -4.9 03/31/2026
Vanguard Capital Management, LLC 4.00 1,930,943 +0.0 03/31/2026
Two Sigma Investments LLC 3.54 1,711,358 -14.0 06/30/2026
BlackRock Inc 2.93 1,414,514 -0.4 03/31/2026
Geode Capital Management, LLC 1.23 596,242 +9.2 03/31/2026
D. E. Shaw & Co LP 1.00 485,025 -13.3 06/30/2026
GMT Capital Corp 0.93 450,100 +0.0 06/30/2026
Susquehanna International Group, LLP 0.93 447,278 -15.3 03/31/2026

Funds

Funds FLNA
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.83 1,365,843 +0.0 07/31/2026
Vanguard Institutional Extnd Mkt Idx Tr 1.17 563,883 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?